Jeil Pharmaceutical

Focus: Jeil Pharmaceutical is a Korean small-molecule drug developer founded in 2017, focused on oncology, cardiovascular, metabolic, neurology, and endocrinology indications. The company operates with a diversified pipeline spanning early-stage discovery through late-stage development.

Oncology Cardiovascular Metabolic Diseases Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Jeil Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Jeil Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

No Intervention

Constipation

N/A

Clinical Trials (1)

NCT04861233A Study of Lubiprostone to Treat Constipation

N/A

Help build intelligence for Jeil Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline with 30 active programs spanning Phase 1-4, offering broad exposure to oncology and metabolic disease development
Multiple Phase 3 programs (JT-001, JT-003, Tamsulosin/Solifenacin combination, JLP-2002) provide near-term regulatory catalysts and career visibility
Geographic anchor in Seoul provides Asian market expansion opportunity and regional regulatory expertise

Watch Out For

No active job openings (0 open positions) suggests limited near-term hiring or organization in transition
Heavy reliance on combination therapies and repositioned assets rather than novel chemical entities limits innovative credential-building
Lack of disclosed funding, revenue, or financial data creates uncertainty about runway, sustainability, and compensation competitiveness

Generated by Claude from Jeil Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

Erosive Gastroesophageal Reflux Disease

N/A

Clinical Trials (1)

NCT07115706JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

N/A

UNI-DEB

Hepatocellular Carcinoma Non-resectable

N/A

Clinical Trials (1)

NCT03564405Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma

N/A

Observationa Study is a Prospective and Multi-institutional Observational Study.

Erosive Reflux Disease

N/A

Clinical Trials (1)

NCT06952855Observationa Study is a Prospective and Multi-institutional Observational Study.

N/A

UNI-DEB

Hepatocellular Carcinoma Non-resectable

N/A

Clinical Trials (1)

NCT03533920Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

N/A

JLP-1401

Hypertension With Dyslipidemia

Phase 1

Clinical Trials (1)

NCT03247140The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Phase 1

telmisartan/amlodipine and atorvastatin

Hypertension With Hyperlipidemia

Phase 1

Clinical Trials (1)

NCT03461081Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers

Phase 1

JPI-547

Advanced Solid Tumors

Phase 1

JPI-289

Stroke

Phase 1

Clinical Trials (1)

NCT02396069The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers

Phase 1

JP-2266

Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT05172622Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects

Phase 1

JLP-2004

Healthy Adult

Phase 1

Clinical Trials (1)

NCT06169059To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

Phase 1

JLP-1901

Healthy Adult

Phase 1

Clinical Trials (1)

NCT06171880To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901

Phase 1

Metformin + Rosuvastatin

Diabetes

Phase 1

Clinical Trials (1)

NCT02982798The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers

Phase 1

JPI-289

Stroke

Phase 1

Clinical Trials (1)

NCT01983358The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers

Phase 1

JLP-1310, Fasted followed by fed

Diabetes

Phase 1

Clinical Trials (1)

NCT02449187Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers

Phase 1

"Metformin" and "Rosuvastatin" seperately

Diabetes

Phase 1

Clinical Trials (1)

NCT03690778The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.

Phase 1

JLP-1401

Hypertension With Dyslipidemia

Phase 1

Clinical Trials (1)

NCT03707899The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

Phase 1

JLP-2002

Overactive Bladder(OAB)

Phase 1

Clinical Trials (1)

NCT04914221The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Phase 1

Rosuvastatin

Hypertension

Phase 1

Clinical Trials (1)

NCT02387619The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine

Phase 1

Metformin

Hyperlipidemia

Phase 1

Clinical Trials (1)

NCT02186483Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

Phase 1

JLP-1207

LUTS

Phase 1

Clinical Trials (1)

NCT02447367Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers

Phase 1

Zeropix

Smoking, Cigarette

Phase 1

Clinical Trials (1)

NCT03362008Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.

Phase 1

Tamsulosin

LUTS

Phase 1

Clinical Trials (1)

NCT02180997Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin

Phase 1

SGLT2 inhibitor

Healthy Adult

Phase 1

Clinical Trials (1)

NCT06165965To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

Phase 1

OIS

Gastrointestinal Neoplasms

Phase 1

Clinical Trials (1)

NCT01693445S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer

Phase 1

JLP-1207

LUTS(Lower Urinary Tract Symptoms)

Phase 1

Clinical Trials (1)

NCT02494349The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.

Phase 1

Cohort 1

Anti-Ulcer Agents

Phase 1

Clinical Trials (1)

NCT03383042Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

Phase 1

KRN1493

Healthy

Phase 1

JLP-2004 qd

Healthy

Phase 1

Clinical Trials (1)

NCT06431399To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004

Phase 1

Irinotecan

Advanced Non-Small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT00874328A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Phase 1/2

Oxaliplatin, Irinotecan, S-1

Biliary Tract Neoplasm

Phase 2

Clinical Trials (1)

NCT02527824Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer

Phase 2

OJP-2028

Essential Hypertension

Phase 2

Clinical Trials (1)

NCT00553865Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets

Phase 2

Esophageal Neoplasms

Phase 2

Clinical Trials (1)

NCT01693432Docetaxel and S-1 for Advanced Esophageal Cancer

Phase 2

Oxaliplatin, Irinotecan, S-1

Stomach Neoplasm

Phase 2

Clinical Trials (1)

NCT02527785Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer

Phase 2

Gemcitabine, UFT

Carcinoma, Non-Small-Cell Lung

Phase 2

Clinical Trials (1)

NCT00625352Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma

Phase 2

Gemcitabine and UFTE chemotherapy

Metastatic or Recurrent Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT01409005Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer

Phase 2

SGLT2 inhibitor

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT06144788Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Phase 2

Gemcitabine, and S-1

Biliary Tract Neoplasm

Phase 2

Clinical Trials (1)

NCT02146703Gemcitabine and S-1 for Advanced Biliary Tract Cancer

Phase 2

GES

Pancreas Neoplasms

Phase 2

Clinical Trials (1)

NCT01693419S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Phase 2

JPI-289 Low-dose

Acute Ischemic Stroke

Phase 2

Clinical Trials (1)

NCT03062397Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Phase 2

JT-001

Type 2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT05101135To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Phase 3

Group I

Dyslipidemia With Hypertension

Phase 3

Clinical Trials (1)

NCT03088254Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Phase 3

JT-003

Type 2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT05296044To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Phase 3

Tamsulosin 0.2mg + Solifenacin 5mg

Lower Urinary Tract Symptoms

Phase 3

Clinical Trials (1)

NCT02972268Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

Phase 3

JLP-2002 A mg

Overactive Bladder

Phase 3

Clinical Trials (1)

NCT04917315To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

Phase 3

Metformin + Rosuvastatin

Type 2 Diabetes

Phase 3

Clinical Trials (1)

NCT02827903Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

Phase 3

Lansoprazole 15 mg

Coronary Artery Disease

Phase 4

Clinical Trials (1)

NCT05820048The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)

Phase 4

cinacalcet

Secondary Hyperparathyroidism

Phase 4

Clinical Trials (1)

NCT01101113Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level

Phase 4

Clopirin 1

ANEURYSM CORONARY ARTERY

Phase 4

Clinical Trials (1)

NCT02410083Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent

Phase 4

Atorvastatin 20mg

Atherosclerosis

Phase 4

Clinical Trials (1)

NCT01341730The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)

Phase 4